A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT ID: NCT02817633

Last Updated: 2025-10-28

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 463 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-08
• Study Completion Date: 2027-03-01

Brief Summary

This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.

Conditions

Neoplasms

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1a: TSR-022 monotherapy

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

Part 1b: TSR-022 in combination with nivolumab

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

Nivolumab

Intervention Type: DRUG

Nivolumab will be administered.

Part 1c: TSR-022 in combination with TSR-042

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Part 1d: TSR-022 in combination with TSR-042 and TSR-033

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

TSR-033

Intervention Type: DRUG

TSR-033 will be administered.

Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Part 1f: TSR-022 in combination with TSR-042 and Docetaxel

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Docetaxel

Intervention Type: DRUG

Docetaxel will be administered.

Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Pemetrexed

Intervention Type: DRUG

Pemetrexed will be administered.

Cisplatin

Intervention Type: DRUG

Cisplatin will be administered.

Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Pemetrexed

Intervention Type: DRUG

Pemetrexed will be administered.

Carboplatin

Intervention Type: DRUG

Carboplatin will be administered.

Part 2: Cohort A Melanoma-TSR-022 as monotherapy

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

Part 2: Cohort A Melanoma-TSR-022 with TSR-042

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

Docetaxel

Intervention Type: DRUG

Docetaxel will be administered.

Part 2: Cohort F- Hepatocellular carcinoma (HCC)-TSR-022 with TSR-042

Group Type: EXPERIMENTAL

TSR-022

Intervention Type: DRUG

TSR-022 will be administered.

TSR-042

Intervention Type: DRUG

TSR-042 will be administered.

Interventions

TSR-022

TSR-022 will be administered.

Intervention Type: DRUG

Nivolumab

Nivolumab will be administered.

Intervention Type: DRUG

TSR-042

TSR-042 will be administered.

Intervention Type: DRUG

TSR-033

TSR-033 will be administered.

Intervention Type: DRUG

Docetaxel

Docetaxel will be administered.

Intervention Type: DRUG

Pemetrexed

Pemetrexed will be administered.

Intervention Type: DRUG

Cisplatin

Cisplatin will be administered.

Intervention Type: DRUG

Carboplatin

Carboplatin will be administered.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant is at least 18 years of age.
• Female participants of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication or be of non-childbearing potential.
• Participant has an ECOG performance status of less than or equal to (<=)1.
• Participant has adequate organ function.

• Participant with advanced or metastatic solid tumor who meets the requirements for the part of the study/cohort he/she will participate in, as follows:
• Participants with advanced or metastatic non-small cell lung carcinoma (NSCLC) that is measurable by CT or MRI per RECIST version 1.1 criteria and meet the following criteria:
• NSCLC histology includes squamous or non-squamous cell carcinoma.
• Participants have received no more than 2 prior lines of therapy, which must include a platinum-based chemotherapy (for example [e.g.], cisplatin, carboplatin) and an anti- programmed death-ligand 1 (PD-L1) antibody.
• Participants must have documented radiographic progression by RECIST version 1.1 criteria on prior anti-programmed cell death protein (PD-1) or anti-PD-L1 therapy.
• Biopsies -All participants enrolled must undergo a biopsy prior to study entry, and the biopsy tissue must be submitted to the central laboratory for all participants in order to determine T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) expression level prior to first dose. If a participant has had a biopsy prior to entering the 35-day screening period and within approximately 12 weeks of study treatment, that biopsy may be accepted as the Baseline fresh biopsy.

• Participant is greater than or equal to (>=)18 years old, is able to understand the study procedures, and agrees to participate in the study by providing written informed consent which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and protocol.
• Participant has histologically or cytologically proven advanced or metastatic NSCLC, and only squamous or non-squamous cell carcinoma.
• Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum-based (eg, cisplatin, carboplatin) doublet chemotherapy regimen and an anti-PD-1 or anti-PD-L1 antibody (no other biologic agents alone or in combination; novel combinations are not allowed). Participants previously treated with targeted therapies, including angiogenesis inhibitors (eg, bevacizumab, ramucirumab, lenvatinib), are not eligible.
• Participant has measurable disease, that is, presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if disease progression has been demonstrated in such lesions and if there are other target lesions. If there is only 1 target lesion that was previously irradiated, the participant is not eligible.
• Participant has documented radiological disease progression on prior platinum-based chemotherapy and on prior anti-PD-1 or anti-PD-L1 therapy according to RECIST v1.1.
• Participant agrees to submit an archival formalin fixed paraffin embedded (FFPE) tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.
• Participant has an ECOG performance status score of 0 or 1.
• Participant has a life expectancy of at least 3 months and is anticipated to be able to complete 4 cycles of docetaxel treatment.
• Participant has adequate organ function as defined in the protocol
• Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Histologically confirmed locally advanced or metastatic and/or unresectable Hepatocellcular Carcinoma (HCC)

• Barcelona Clinic Liver Cancer Stage B or C
• Cirrhosis grade of Child-Pugh Class A
• No prior systemic therapy for HCC
• Documented HBV testing at screening, including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAB) and hepatitis B core antibody (HBcAb). Participants with a positive HBsAg will require negative hepatitis B virus (HBV) DNA testing at screening.

• Participants with chronic HBV infection (HBsAg +) are required to be receiving effective antiviral therapy (i.e., with Tenofovir or Entecavir) for at least 14 days with willingness to continue for the length of the study and have HBV deoxyribonucleic acid (DNA) less than 100 International Units Per Milliliter (IU/mL) within 28 days prior to initiation of study treatment.
• Participants with chronic HBV infection (HBsAg+) require documented Hepatitis D virus (HDV) antibody testing conducted at screening. If HDV antibody is positive, then HDV ribonucleic acid (RNA) must be negative to participate.
• Participants with a negative HBsAg and positive HBcAb result are eligible only if HBV DNA is negative (Past HBV participants).
• Documented hepatitis C virus (HCV) antibody testing conducted at screening. If HCV antibody is positive, then HCV RNA must be negative. Participants with recently treated HCV prior to study start must be greater than (>)12 weeks from final HCV treatment.
• Must have measurable disease, defined as at least one tumor lesion that can be accurately measured according to RECIST v1.1
• Participant agrees to submit an archival FFPE tumor tissue specimen that was collected on or after diagnosis of metastatic disease from location(s) not irradiated prior to biopsy. Both tissue block and freshly cut slides are acceptable. If archival tissue is not available, the participant must undergo biopsy prior to study entry.

• Participants are also encouraged, but not required, to have a fresh tumor tissue biopsy of a primary or metastatic tumor prior to dosing (samples will be used to enable biomarker analysis).
• International normalized ratio (INR) or prothrombin time (PT) <= 2× upper limit of normal (ULN) unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) <=2×ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
• Negative human immunodeficiency virus (HIV) test at screening The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

Exclusion Criteria

• History of Grade greater than or equal to (>=)3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities.
• Participant has known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may be included only after discussion with the Medical Monitor.
• Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy.
• Participant is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.
• Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

• A participant with negative (as determined by Central Testing Lab) or unevaluable TIM-3 expression from tissue obtained prior to study entry will not be eligible for the study.
• Participant has received prior therapy as defined below:
• Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE.
• Prior treatment with an anti-lymphocyte activation gene (LAG)-3 or anti-TIM-3.
• Radiologic or clinical progression <= 8 weeks after initiation of prior anti-PD-1 or anti-PD-L1 antibody.
• Participants with known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) translocation, or receptor tyrosine kinase (ROS1) mutation.
• Participant has received a vaccine other than a vaccine against severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) infection ("Coronavirus Disease 2019" [COVID-19]) within 7 days of planned start of study therapy. The use of all COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the recombinant adenoviral vector platform within 30 days of planned start of study therapy. If a COVID-19 vaccine using this platform is to be administered within 30 days of planned start of study therapy, this must first be discussed with and approved by the Sponsor's Medical Monitor.

• Participant has been previously treated with an anti PD 1, anti PD L1, or anti PD L2 agent that resulted in permanent discontinuation due to an AE
• Participant has been previously treated with an anti TIM-3 or anti cytotoxic T lymphocyte-associated protein 4 (CTLA 4) agent or docetaxel.
• Participant has a documented sensitizing EGFR, ALK, or ROS-1 mutation. Participants whose tumors have not been tested for these driver mutations and therefore who have unknown driver mutation status are not eligible. Participants with squamous histology do not need to be tested for these driver mutations.
• Participant had radiological or clinical disease progression (that is [ie,] worsening performance status, clinical symptoms, and laboratory data) <=8 weeks after initiation of prior anti PD 1 or anti-PD-L1 antibody. The clinical disease progression should have been confirmed by a subsequent radiological scan.
• Participant has received radiation to the lung that is >30 Gray (Gy) within 6 months prior to the first dose of study treatment.
• Participant has completed palliative radiotherapy within 7 days prior to the first dose of study treatment.
• Participant has an additional malignancy or a history of prior malignancy, with the exception of adequately treated basal or squamous skin cancer, cervical carcinoma in situ, or bladder carcinoma in situ without evidence of disease, or had a malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
• Participant has known new or progressive brain metastases and/or leptomeningeal metastases. Participants who have received prior therapy for their brain metastases and have radiologically stable central nervous system disease may participate, provided they are neurologically stable for at least 4 weeks before study entry and are off corticosteroids within 3 days prior to the first dose of study treatment.
• Participant has tested positive for the following at Screening or within 3 months before the first dose of study treatment:
• Presence of hepatitis B surface antigen.
• Presence of hepatitis C antibody in the absence of an Ribonucleic acid (RNA) test for hepatitis C virus.
• Participant has known human immunodeficiency virus (HIV) (positive for HIV 1 or HIV 2 antibodies).
• Participant has active autoimmune disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy of prednisone, or equivalent, for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
• Participant has received systemic steroid therapy within 3 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
• Participant has current interstitial lung disease, current pneumonitis, or a history of pneumonitis that required the use of glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.
• Participant does not meet requirements per local prescribing guidelines for receiving treatment with docetaxel, including severe hypersensitivity reactions to drugs formulated with polysorbate 80.
• Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.

• Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
• Participant must not have had major surgery <= 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
• Participants must not have received investigational therapy <= 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy.
• Active or untreated central nervous system (CNS) and leptomeningeal metastases
• Prior therapy with any medication targeting PD-1, PD-L1, or TIM-3
• Participant must not have a known hypersensitivity to TSR-042 and TSR-022 components or excipients.
• Participants with active malignancy (other than HCC) or a prior malignancy within the past 2 years are excluded. Participants with completely resected cutaneous melanoma (early stage), basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in-situ, breast carcinoma in-situ, and localized prostate cancer are eligible
• Participant must not have serious, uncontrolled medical disorder, or nonmalignant systemic disease as determined by the treating physician. Examples include, but are not limited to uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, or superior vena cava syndrome.
• Has a history or evidence of cardiac abnormalities within the 6 months prior to enrollment, including:

• Serious, uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities including second-degree (Type II) or third-degree atrioventricular (AV) block.
• Cardiomyopathy, myocarditis, myocardial infarction, acute coronary syndromes (including angina pectoris), coronary angioplasty, stenting, or bypass grafting.
• Congestive heart failure [New York Heart Association (NYHA) Class III or IV]
• Symptomatic pericarditis
• Known history of HIV infection
• Active tuberculosis infection or other microbial infection or any active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
• Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (. i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• History of idiopathic pulmonary fibrosis, interstitial lung disease, bronchial asthma, organizing pneumonia, bronchiolitis obliterans, drug-induced pneumonitis, or idiopathic pneumonitis
• History of organ transplantation including allogeneic bone marrow transplantation
• Participant has a diagnosis of immunodeficiency or has been receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.
• Participant has received a live vaccine within 7 days of initiating protocol therapy. Seasonal flu vaccines that do not contain live virus and COVID 19 vaccines are permitted.
• Psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant, lactating, breastfeeding, or intending to become pregnant during the study and for 150 days after the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tesaro, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Goodyear, Arizona, United States

GSK Investigational Site

Scottsdale, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Encinitas, California, United States

GSK Investigational Site

Fountain Valley, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

San Marcos, California, United States

GSK Investigational Site

Whittier, California, United States

GSK Investigational Site

Aurora, Colorado, United States

GSK Investigational Site

Aurora, Colorado, United States

GSK Investigational Site

Denver, Colorado, United States

GSK Investigational Site

New Haven, Connecticut, United States

GSK Investigational Site

Washington D.C., District of Columbia, United States

GSK Investigational Site

Jacksonville, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Sarasota, Florida, United States

GSK Investigational Site

Tampa, Florida, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Augusta, Georgia, United States

GSK Investigational Site

Arlington Heights, Illinois, United States

GSK Investigational Site

Chicago, Illinois, United States

GSK Investigational Site

Niles, Illinois, United States

GSK Investigational Site

Iowa City, Iowa, United States

GSK Investigational Site

Wichita, Kansas, United States

GSK Investigational Site

Louisville, Kentucky, United States

GSK Investigational Site

Pikeville, Kentucky, United States

GSK Investigational Site

Wheaton, Maryland, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Detroit, Michigan, United States

GSK Investigational Site

Rochester, Minnesota, United States

GSK Investigational Site

Florissant, Missouri, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

Hackensack, New Jersey, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

The Bronx, New York, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Cleveland, Ohio, United States

GSK Investigational Site

Toledo, Ohio, United States

GSK Investigational Site

Eugene, Oregon, United States

GSK Investigational Site

Vancouver, Oregon, United States

GSK Investigational Site

Bethlehem, Pennsylvania, United States

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

GSK Investigational Site

Charleston, South Carolina, United States

GSK Investigational Site

Greenville, South Carolina, United States

GSK Investigational Site

Nashville, Tennessee, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Fort Worth, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

Longview, Texas, United States

GSK Investigational Site

McAllen, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Temple, Texas, United States

GSK Investigational Site

Tyler, Texas, United States

GSK Investigational Site

Fairfax, Virginia, United States

GSK Investigational Site

Kennewick, Washington, United States

GSK Investigational Site

Puyallup, Washington, United States

GSK Investigational Site

Seattle, Washington, United States

GSK Investigational Site

Tacoma, Washington, United States

GSK Investigational Site

Madison, Wisconsin, United States

GSK Investigational Site

Daegu, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

Girona, , Spain

GSK Investigational Site

Jerez de la Frontera, , Spain

GSK Investigational Site

L'Hospitalet de Llobrega, , Spain

GSK Investigational Site

Las Palmas de Gran Canar, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Málaga, , Spain

GSK Investigational Site

Palma de Mallorca, , Spain

GSK Investigational Site

Pamplona, , Spain

GSK Investigational Site

Santander, , Spain

GSK Investigational Site

Seville, , Spain

GSK Investigational Site

Valencia, , Spain

GSK Investigational Site

Valencia, , Spain

GSK Investigational Site

Zaragoza, , Spain

Countries

United States; South Korea; Spain

Other Identifiers

2018-002143-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

213348

Identifier Type: -

Identifier Source: org_study_id

NCT06322693

Identifier Type: -

Identifier Source: nct_alias